Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

GERN

Geron Corp.

May 17 • 04:00PM ET

3.81

Dollar change -0.09
Percentage change -2.31	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF PJP IWO IBB SCHA VTWO LABU VHT

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	15.67%	Shs Outstand	544.91M	Perf Week	0.26%
Market Cap	2.26B	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-0.04%	Shs Float	500.20M	Perf Month	2.14%
Income	-201.40M	PEG	-	EPS next Q	-0.10	Inst Own	58.53%	Short Float	10.46%	Perf Quarter	82.30%
Sales	0.52M	P/S	4345.82	EPS this Y	-5.80%	Inst Trans	-1.65%	Short Ratio	4.03	Perf Half Y	99.48%
Book/sh	0.58	P/B	6.53	EPS next Y	54.43%	ROA	-44.41%	Short Interest	52.34M	Perf Year	27.42%
Cash/sh	0.75	P/C	5.09	EPS next 5Y	5.00%	ROE	-60.04%	52W Range	1.64 - 4.30	Perf YTD	80.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.08%	ROI	-56.11%	52W High	-11.40%	Beta	0.44
Dividend TTM	-	Quick Ratio	3.67	Sales past 5Y	46.26%	Gross Margin	-	52W Low	132.32%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	3.67	EPS Y/Y TTM	-0.29%	Oper. Margin	-40381.92%	RSI (14)	54.01	Volatility	4.79% 6.41%
Employees	141	Debt/Eq	0.25	Sales Y/Y TTM	5.26%	Profit Margin	-38730.00%	Recom	1.29	Target Price	6.07
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-31.14%	Payout	-	Rel Volume	0.53	Prev Close	3.90
Sales Surprise	955.56%	EPS Surprise	5.96%	Sales Q/Q	1347.62%	Earnings	May 02 BMO	Avg Volume	13.00M	Price	3.81
SMA20	0.01%	SMA50	12.38%	SMA200	55.78%	Trades		Volume	6,917,557	Change	-2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral	$4.50
Apr-29-24	Initiated	TD Cowen	Buy	$10
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4
Apr-09-19	Upgrade	Needham	Hold → Buy	$3
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy	$1.50 → $3.25
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral	$5.75 → $1.50
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy	$5.75
Sep-13-16	Reiterated	FBR Capital	Outperform	$6 → $5
Sep-13-16	Reiterated	FBR & Co.	Outperform	$6 → $5
Dec-07-15	Reiterated	Piper Jaffray	Overweight	$5 → $10

Show Previous Ratings

May-16-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-24 10:34AM	Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 12:55PM	GERN Stock Earnings: Geron Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:20AM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:46AM	Loading…
06:46AM	The Top 3 Penny Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 04:30PM	Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-03-24 04:30PM	Geron to Participate at Upcoming Investor Conferences in April (Business Wire)
Mar-19-24 09:07AM	Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Mar-15-24 03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video) +92.00%
01:29PM	Stocks to Watch Friday: Adobe, Ulta, Fisker (The Wall Street Journal)
10:47AM	Why Is Geron (GERN) Stock Up 94% Today? (InvestorPlace)
08:57AM	Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up (Zacks)
05:00AM	Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat (FierceBiotech.com)
03:54PM	Loading…
Mar-14-24 03:54PM	Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS (Business Wire)
Mar-13-24 10:48AM	Implied Volatility Surging for Geron (GERN) Stock Options (Zacks) -6.91%
Mar-12-24 12:28PM	Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat (FierceBiotech.com) -12.15%
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Feb-28-24 07:05AM	Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.57%
Feb-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-14-24 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (Business Wire)
Jan-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-24 08:30AM	Geron to Participate in the B. Riley Securities Virtual Oncology Conference (Business Wire)
Dec-21-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-23 04:15PM	Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS (Business Wire) -6.76%
Dec-06-23 08:00AM	Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis (Business Wire)
Dec-04-23 05:00AM	Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS (Business Wire) -6.53%
Nov-28-23 08:00AM	Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors (Business Wire)
Nov-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Loading…
Nov-07-23 04:30PM	Geron to Participate at Upcoming Investor Conferences in November (Business Wire)
Nov-02-23 09:00AM	Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS (Business Wire) -7.77%
08:00AM	Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 04:30PM	Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-23 03:26PM	Buy These 2 Beaten-Down Stocks, Goldman Sachs Says, Forecasting up to 130% Upside (TipRanks) -5.41%
Sep-29-23 08:00AM	Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Sep-11-23 04:30PM	Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer (Business Wire)
Sep-07-23 08:00AM	Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-05-23 04:30PM	Geron to Participate in the Baird 2023 Global Healthcare Conference (Business Wire)
Aug-22-23 08:00AM	Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS (Business Wire) -13.31%
Aug-21-23 08:00AM	Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Aug-17-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.56%
Aug-03-23 04:05PM	Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 04:30PM	Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire)
Jul-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 08:30AM	Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS (Business Wire)
Jun-22-23 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-20-23 09:00AM	Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat (Business Wire) +5.00%
Jun-13-23 09:00AM	Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS (Business Wire)
Jun-12-23 08:00AM	Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients (Business Wire) -5.83%
Jun-07-23 04:30PM	Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-06-23 04:30PM	Geron to Host Virtual Investor Event on June 14, 2023 (Business Wire)
Jun-02-23 03:30PM	Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients (Business Wire) +6.51%
May-25-23 05:02PM	Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
May-18-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-11-23 10:02AM	Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
08:00AM	Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-04-23 04:30PM	Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-26-23 10:05AM	Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial (Business Wire)
Apr-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-12-23 04:40PM	Geron to Present at Upcoming Investor Conferences in April (Business Wire)
Mar-16-23 05:45PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:05PM	Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones (Business Wire)
Mar-09-23 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023 (Business Wire)
Feb-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-23 01:19PM	10 Hot Healthcare Stocks To Buy Now (Insider Monkey)
Jan-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-23 07:30AM	Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (Business Wire)
Jan-11-23 07:30AM	Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S. (Business Wire)
Jan-10-23 04:30PM	Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million (Business Wire) +11.86%
Jan-05-23 11:15PM	Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -22.26%
Jan-04-23 04:19PM	Geron Corporation Announces Proposed Public Offering of Common Stock (Business Wire) +32.92%
06:55AM	Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS (Business Wire)
Jan-03-23 04:30PM	Geron Announces Conference Call for Top-Line Results from IMerge Phase 3 (Business Wire)
Dec-22-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-22 11:10AM	10 Penny Stocks That Can Grow Big in 2023 (Insider Monkey)
Dec-12-22 08:00AM	Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients (Business Wire)
Dec-08-22 11:30AM	Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-22 11:30AM	Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report? (Zacks)
Dec-04-22 05:19PM	TipRanks Perfect 10 List: 2 Stocks Under $5 That Are Worth Looking Into (TipRanks)
Nov-17-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-22 04:30PM	Geron to Participate in Stifel 2022 Healthcare Conference (Business Wire)
Nov-04-22 12:00AM	Geron (GERN) Q3 2022 Earnings Call Transcript (Motley Fool)
Nov-03-22 09:25AM	Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.58%
09:01AM	Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS (Business Wire)
08:00AM	Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones (Business Wire)
Oct-27-22 04:30PM	Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-25-22 06:15AM	Investing in Geron (NASDAQ:GERN) a year ago would have delivered you a 55% gain (Simply Wall St.)
Oct-24-22 09:40AM	Is Geron (GERN) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-20-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-14-22 06:43AM	Geron Corporation's (NASDAQ:GERN) Intrinsic Value Is Potentially 95% Above Its Share Price (Simply Wall St.)
Sep-08-22 04:15PM	Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors (Business Wire)
Sep-01-22 04:30PM	Geron to Present at Upcoming Investor Conferences (Business Wire)
Aug-31-22 04:55PM	Top Penny Stocks for September 2022 (Investopedia) +14.78%
04:33PM	Why Geron's Shares Rose 14.78% on Wednesday (Motley Fool)
Aug-22-22 04:15PM	Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis (Business Wire)
09:11AM	10 Best Penny Stocks to Invest $100 (Insider Monkey)
Aug-18-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAWLIS V BRYAN	Director	May 15 '24	Option Exercise	1.94	35,000	67,900	35,000	May 17 04:05 PM
LAWLIS V BRYAN	Director	May 15 '24	Sale	3.75	35,000	131,250	0	May 17 04:05 PM
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,607	15,064	7,407	Aug 24 08:52 PM
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,579	15,000	26,220	Aug 24 08:52 PM

Open in Screener

BMRN

Biomarin Pharmaceutical Inc.

May 17 • 04:00PM ET

77.56

Dollar change +0.59
Percentage change 0.77	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

BMRN Biomarin Pharmaceutical Inc. daily Stock Chart

Held by: VTI VO VXF VUG VOT IBB USMV VHT IWR SCHM

Index	-	P/E	72.59	EPS (ttm)	1.07	Insider Own	2.01%	Shs Outstand	188.60M	Perf Week	-4.28%
Market Cap	14.73B	Forward P/E	29.09	EPS next Y	2.67	Insider Trans	-5.68%	Shs Float	186.06M	Perf Month	-13.89%
Income	205.46M	PEG	1.69	EPS next Q	0.33	Inst Own	99.32%	Short Float	2.10%	Perf Quarter	-12.63%
Sales	2.48B	P/S	5.95	EPS this Y	98.28%	Inst Trans	2.04%	Short Ratio	2.45	Perf Half Y	-10.91%
Book/sh	26.74	P/B	2.90	EPS next Y	54.58%	ROA	3.09%	Short Interest	3.91M	Perf Year	-15.94%
Cash/sh	5.51	P/C	14.07	EPS next 5Y	43.00%	ROE	4.22%	52W Range	76.02 - 99.56	Perf YTD	-19.56%
Dividend Est.	-	P/FCF	81.00	EPS past 5Y	-	ROI	3.63%	52W High	-22.10%	Beta	0.32
Dividend TTM	-	Quick Ratio	1.70	Sales past 5Y	10.23%	Gross Margin	76.81%	52W Low	2.03%	ATR (14)	2.11
Dividend Ex-Date	-	Current Ratio	2.74	EPS Y/Y TTM	183.46%	Oper. Margin	8.60%	RSI (14)	32.11	Volatility	2.43% 2.59%
Employees	3401	Debt/Eq	0.22	Sales Y/Y TTM	16.45%	Profit Margin	8.30%	Recom	1.74	Target Price	108.06
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	75.38%	Payout	0.00%	Rel Volume	2.15	Prev Close	76.97
Sales Surprise	-0.46%	EPS Surprise	47.53%	Sales Q/Q	9.61%	Earnings	Apr 24 AMC	Avg Volume	1.59M	Price	77.56
SMA20	-6.76%	SMA50	-9.41%	SMA200	-12.51%	Trades		Volume	3,433,406	Change	0.77%

Date	Action	Analyst	Rating Change	Price Target Change
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$110
Jun-13-22	Resumed	Wedbush	Neutral	$146 → $70
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$96 → $113
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy	$100

Show Previous Ratings

Today 05:06AM	4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-13-24 04:14PM	Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing (MT Newswires)
May-09-24 06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 08:00AM	BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV (PR Newswire)
07:00PM	Loading…
May-06-24 07:00PM	Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ... (GuruFocus.com)
04:47PM	Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing (MT Newswires)
May-04-24 04:00PM	New Data for BioMarin's VOXZOGO (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting (PR Newswire)
May-03-24 02:31PM	Citi Just Cut Its Price Target on These 3 Stocks (InvestorPlace)
Apr-29-24 02:26PM	BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says (MT Newswires)
Apr-27-24 05:06AM	4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
01:07AM	Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) (GuruFocus.com)
Apr-26-24 08:49AM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:53AM	Pfizer hemophilia gene therapy arrives in US to uncertain future (BioPharma Dive)
Apr-25-24 01:30PM	CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.90%
11:48AM	Loading…
11:48AM	BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales (Zacks)
11:44AM	Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating (MT Newswires)
10:47AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
10:31AM	Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating (MT Newswires)
07:39AM	BioMarin drops drug programs in pipeline cull (BioPharma Dive)
06:46AM	Q1 2024 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
03:19AM	Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
Apr-24-24 06:30PM	BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:33PM	BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates (GuruFocus.com)
05:15PM	BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates (Zacks)
04:23PM	BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours (MT Newswires)
04:14PM	BioMarin: Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Reports Record Financial Results for the First Quarter 2024 (PR Newswire)
Apr-23-24 11:36AM	Is a Surprise Coming for BioMarin (BMRN) This Earnings Season? (Zacks)
Apr-22-24 04:26PM	BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says (MT Newswires)
09:16AM	Loading…
09:16AM	Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Apr-17-24 10:01AM	BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-12-24 07:00PM	Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ... (GuruFocus.com)
Apr-10-24 08:00AM	BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET (PR Newswire)
Apr-01-24 07:01PM	Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ... (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 05:06AM	4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
Mar-12-24 08:30AM	New Data to be Presented for BioMarin's VOXZOGO (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-11-24 10:00AM	BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth (GuruFocus.com)
Mar-08-24 01:31AM	Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ... (GuruFocus.com)
Mar-07-24 08:30AM	BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer (PR Newswire)
Mar-01-24 09:00AM	BioMarin Scheduled to Participate in March Investor Conferences (PR Newswire)
Feb-27-24 12:03AM	Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight (GuruFocus.com)
Feb-26-24 02:36PM	REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies (Reuters)
02:12PM	REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs (Reuters)
Feb-23-24 04:29PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:33PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:34AM	BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales (Zacks)
07:21AM	Q4 2023 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
05:43AM	20 Fastest Growing Biotech Companies in the US (Insider Monkey)
04:25AM	BioMarin preaches patience amid slow sales for hemophilia gene therapy (BioPharma Dive)
Feb-22-24 06:00PM	Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings (Zacks)
05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:42PM	BioMarin Pharmaceutical Inc. (BMRN) Announces Record Financial Results for 2023 (GuruFocus.com)
04:23PM	BioMarin: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 (PR Newswire)
Feb-19-24 09:15AM	Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Feb-15-24 10:00AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 01:10PM	PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc (GuruFocus.com)
Feb-08-24 04:10PM	7 Biotech Stocks Fighting Americas Deadliest Diseases (InvestorPlace)
08:00AM	BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET (PR Newswire)
Feb-07-24 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Feb-06-24 08:30AM	BioMarin to Present ROCTAVIAN (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress (PR Newswire)
Jan-24-24 11:21AM	Here's Why Investors May Bet on BioMarin (BMRN) Stock Now (Zacks)
Jan-23-24 08:00AM	Catalyst Pharmaceuticals: An Attractive Biopharma Bet (GuruFocus.com)
Jan-20-24 05:06AM	4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Jan-15-24 09:45AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Jan-03-24 08:00AM	BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA (PR Newswire)
Dec-21-23 06:14AM	BioMarin strikes deal with Elliott, agrees to review business (BioPharma Dive)
Dec-20-23 05:08PM	BioMarin settles with Elliott, adds 3 independent directors (Reuters)
04:05PM	BioMarin Announces Governance Enhancements and Value Creation Initiatives (PR Newswire)
Dec-14-23 07:05PM	Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ... (GuruFocus.com)
Dec-05-23 11:01AM	Billionaire Louis Bacons 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Dec-02-23 05:06AM	4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-01-23 11:31AM	Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report? (Zacks)
Nov-29-23 09:13PM	Elfun Trusts Sheds Qualcomm in Q3, Embraces New Holdings (GuruFocus.com)
06:30AM	BioMarin secures hemophilia gene therapy coverage in Germany (BioPharma Dive)
Nov-28-23 11:09AM	BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany (Reuters)
08:30AM	BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany (PR Newswire)
Nov-16-23 08:47AM	3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN) (Entrepreneur: Stocks)
Nov-10-23 12:58AM	BioMarin gains on report Elliott has a stake: Insider trades & hedge funds weekly (Investing.com)
Nov-09-23 04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace)
Nov-07-23 07:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research) +12.16%
05:07PM	BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake (Investor's Business Daily)
02:24PM	BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals (InvestorPlace)
Nov-06-23 07:20PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Nov-04-23 05:06AM	4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Nov-03-23 01:23AM	The Biomarin Pharmaceutical Inc (BMRN) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-02-23 05:02PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.17%
12:17PM	BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut (Zacks)
08:44AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
07:15AM	BioMarin to replace CEO Bienaimé with Genentech veteran (BioPharma Dive)
Nov-01-23 06:30PM	BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Biomarin Pharmaceutical Inc (BMRN) Reports 15% Total Revenue Growth in Q3 2023 (GuruFocus.com)
05:02PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year (PR Newswire)
04:02PM	BioMarin Announces Retirement of Jean-Jacques Bienaim; Appoints Alexander Hardy President and Chief Executive Officer (PR Newswire)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	May 10 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Sale	81.14	20,000	1,622,800	474,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Sale	81.62	20,000	1,632,400	474,994	May 13 03:57 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Option Exercise	63.10	1,850	116,735	58,007	May 06 04:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	May 02 '24	Sale	82.91	5,000	414,550	66,767	May 06 04:40 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Sale	85.01	1,850	157,268	56,157	May 06 04:45 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Sale	91.26	20,000	1,825,200	474,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Sale	90.99	20,000	1,819,800	474,994	Apr 15 04:21 PM
Burkhart Erin	GVP, Chief Accounting Officer	Apr 10 '24	Sale	90.00	2,286	205,740	16,156	Apr 12 03:07 PM
Davis George Eric	EVP, Chief Legal Officer	Mar 28 '24	Sale	88.34	24,602	2,173,341	55,856	Apr 01 04:54 PM
Slamon Dennis	Director	Mar 18 '24	Option Exercise	79.70	10,000	797,000	40,809	Mar 20 05:13 PM
BIENAIME JEAN JACQUES	Director	Mar 06 '24	Sale	86.71	1,000	86,713	560,203	Mar 07 05:35 PM
FUCHS HENRY J	President, Worldwide R&D	Mar 05 '24	Sale	85.18	35,341	3,010,396	212,117	Mar 07 06:54 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 05 '24	Sale	87.07	4,000	348,280	94,047	Mar 07 05:32 PM
BIENAIME JEAN JACQUES	Director	Mar 05 '24	Sale	85.51	1,000	85,510	561,203	Mar 07 05:35 PM
BIENAIME JEAN JACQUES	Director	Feb 27 '24	Sale	90.35	1,000	90,350	562,203	Feb 29 05:05 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Sale	88.28	15,000	1,324,200	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Sale	89.77	15,000	1,346,550	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Sale	96.38	10,000	963,800	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Sale	98.19	10,000	981,900	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Option Exercise	63.10	10,000	631,000	435,112	Dec 22 05:14 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Sale	93.99	10,000	939,900	425,112	Dec 22 05:14 PM
Davis George Eric	EVP, Chief Legal Officer	Dec 13 '23	Sale	95.30	13,764	1,311,709	55,710	Dec 14 06:18 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Aug 16 '23	Sale	90.00	5,000	450,000	60,804	Aug 17 03:57 PM
FUCHS HENRY J	President, Worldwide R&D	Aug 10 '23	Sale	90.43	12,000	1,085,111	176,187	Aug 11 01:59 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Aug 09 '23	Sale	93.30	5,360	500,109	40,041	Aug 10 04:47 PM
Davis George Eric	EVP, Chief Legal Officer	Aug 08 '23	Sale	89.42	11,000	983,662	69,474	Aug 09 07:08 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 08 '23	Sale	88.29	6,000	529,740	422,732	Aug 09 07:05 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 07 '23	Sale	88.10	4,000	352,400	428,732	Aug 09 07:05 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GERN

Geron Corp.

BMRN

Biomarin Pharmaceutical Inc.

Upgrade your FINVIZ experience